Rapid Micro Biosystems Inc

Rapid Micro Biosystems Inc

RPID · NASDAQ · Healthcare / Medical Devices

0.651USD-0.02 (-2.98%)

Price History

Full chart

Market Stats

Previous Close0.671
Open0.67
Day Range0.632 – 0.675
52-Week Range1.08 – 4.94
Volume91.55K
Market Cap55.68M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.11
Dividend Yield0.00%
Beta1.44
50-Day Avg1.63
200-Day Avg2.56

About

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Robert G. Spignesi Jr.
  • Employees171
  • Headquarters25 Hartwell Avenue, Lexington, MA, United States, 02421, USA
  • Websitehttps://www.rapidmicrobio.com

Leadership

  • Mr. Robert G. Spignesi Jr.CEO, President, COO & Director · b. 1970
  • Mr. Sean M. Wirtjes CPAChief Financial Officer · b. 1969
  • Mr. Michael Beaulieu C.F.A.Vice President of Investor Relations & Corporate Communications
  • Mr. James XuSenior VP of Legal & Secretary
  • Ms. Katherine AtkinsonSenior VP of Global Sales & Marketing
  • Ms. Julie JarvieSenior VP of Human Resources
  • Mr. Chris RobinsonSenior Vice President of Operations

Financials

Income Statement

Currency: USD2010-12-312011-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue16.08M10.97M16.51M16.08M23.23M17.13M22.52M28.05M33.59M
Growth (%)--31.79%+50.56%-2.63%+44.50%-26.25%+31.44%+24.57%+19.74%
Cost of Revenue16.02M11.78M16.75M24.15M30.97M25.67M28.00M28.16M25.98M
Gross Profit59.00K--234.00K-8.07M-7.74M-8.54M-5.49M-109.00K7.61M
Gross Margin0.37%--1.42%-50.20%-33.32%-49.85%-24.36%-0.39%22.65%
Operating Expense--18.40M22.47M39.49M54.68M51.08M49.81M55.00M
Operating Income---18.63M-30.54M-47.23M-63.22M-56.56M-49.92M-47.39M
Operating Margin---112.85%-189.96%-203.31%-368.99%-251.18%-177.96%-141.10%
EBITDA---16.87M-32.00M-69.25M-60.38M-49.33M-43.51M-42.74M
EBITDA Margin---102.16%-199.02%-298.10%-352.43%-219.06%-155.09%-127.25%
Net Income---21.17M-37.08M-73.52M-60.81M-52.47M-46.89M-47.12M
Net Income Margin---128.22%-230.63%-316.48%-354.91%-232.99%-167.16%-140.30%
R&D--5.43M6.53M9.78M12.87M12.82M14.60M13.60M
R&D as % of Total Revenue--32.88%40.62%42.10%75.09%56.93%52.04%40.50%
Interest Expense002.38M3.45M2.65M1.78M-40.00K1.09M
Interest Expense % of Total Revenue0.00%0.00%14.38%21.44%11.41%10.38%-0.14%3.25%

Balance Sheet

Currency: USD2010-12-312011-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.32M1.66M31.69M70.00M241.17M190.65M143.45M98.17M74.85M
Total Liabilities5.02M6.84M32.41M45.18M20.19M26.48M25.46M22.82M41.65M
Total Equity-2.70M-5.17M-725.00K24.82M220.98M164.17M117.99M75.35M33.21M
Cash156.00K1.00K12.46M30.08M178.39M27.06M24.29M16.91M20.03M
Total Debt--17.81M24.81M400.00K7.97M7.35M6.17M23.87M
Net Debt--5.35M-5.27M-178.39M-19.10M-16.94M-10.74M3.84M

Cash Flow

Currency: USD2010-12-312011-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---21.15M-31.00M-54.96M-58.55M-45.08M-44.15M-31.06M
Investing Cash Flow---1.70M-15.67M-13.29M-93.47M42.15M36.66M14.33M
Financing Cash Flow1.52M2.99M14.87M64.23M216.75M693.00K149.00K203.00K19.77M
Capital Expenditure6.00K3.00K1.70M690.00K3.22M6.74M1.84M1.36M850.00K
Free Cash Flow---22.84M-31.69M-58.18M-65.29M-46.93M-45.52M-31.91M
Dividends Paid-----566.00K186.00K--
FCF to OCF--108.02%102.23%105.85%111.51%104.09%103.09%102.74%
Dividend Paid to FCF------0.87%-0.40%--

Earnings

Report DateJun 2, 2021Aug 26, 2021Nov 11, 2021Mar 4, 2022May 10, 2022Aug 12, 2022Nov 10, 2022Mar 3, 2023May 5, 2023Aug 4, 2023Nov 3, 2023Mar 1, 2024May 3, 2024Aug 2, 2024Nov 1, 2024Feb 28, 2025May 9, 2025Aug 12, 2025Nov 7, 2025Mar 12, 2026May 7, 2026Aug 7, 2026Nov 6, 2026
EPS Estimate0.00-0.40-0.39-0.28-0.32-0.35-0.36-0.36-0.36-0.33-0.28-0.30-0.29-0.28-0.25-0.21-0.27-0.25-0.24-0.23-0.21-0.26-0.19
EPS Actual-0.69-20.01-0.39-0.35-0.35-0.31-0.38-0.39-0.32-0.33-0.31-0.26-0.31-0.29-0.26-0.22-0.26-0.27-0.26-0.28-0.31-0.27-
Surprise--4902.50%0.00%-25.00%-9.38%11.43%-5.56%-8.33%11.11%0.00%-10.71%13.33%-6.90%-3.57%-4.00%-4.76%3.70%-8.00%-8.33%-21.74%-47.62%-3.85%-
Timing-After-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap55.68M
Enterprise Value59.39M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales1.58
Price / Book3.14
EPS-1.11
Book Value0.355
Revenue (TTM)35.18M
Gross Profit (TTM)1.95M
EBITDA-47.08M
Profit Margin-145.55%
Operating Margin-152.99%
Return on Equity-141.65%
Return on Assets-46.40%
Shares Outstanding45.66M
Shares Float23.91M
Beta1.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 3 analystsTarget 6.67
  • Strong Buy
    3

Ownership Breakdown

Institutions
46.13%
Insiders
10.11%
Retail / Other
43.76%

Top Institutional Holders

  • Bain Capital Life Sciences Investors, LLC
    8.43M16.82%
  • ABG-WTT Global Life Science Capital Partners GP Ltd
    1.85M3.68%
  • Vanguard Capital Management, LLC
    982.49K1.96%
  • Evernest Financial Advisors LLC
    506.00K1.01%
  • Advent International LP
    379.79K0.76%
  • Essex Investment Management Company, LLC
    362.70K0.72%
  • SEI Investments Co
    284.82K0.57%
  • Geode Capital Management, LLC
    247.18K0.49%
  • Millennium Management LLC
    236.60K0.47%
  • Susquehanna International Group, LLP
    212.11K0.42%
  • BlackRock Inc
    157.23K0.31%
  • Jane Street Group LLC
    132.93K0.27%
  • Renaissance Technologies Corp
    126.62K0.25%
  • 683 Capital Management LLC
    120.77K0.24%
  • Legato Capital Management LLC
    119.53K0.24%
  • Vanguard Fiduciary Trust Co
    109.71K0.22%
  • Dimensional Fund Advisors, Inc.
    104.19K0.21%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    750.98K1.50%
  • iShares Micro-Cap ETF
    111.39K0.22%
  • Fidelity Extended Market Index
    103.38K0.21%

Stock Splits

  • Oct 29, 20101:30